• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Data backs gene therapy delivery system for treating type 2 diabetes from Fractyl Health

December 5, 2022 By Sean Whooley

Fractyl-Logo-CMYK-June2021-02Fractyl Health today announced positive preclinical proof-of-concept data in an animal model for its gene therapy delivery platform for treating type 2 diabetes.

The company, which develops the Revita diabetes reversal procedure, evaluated its Rejuva program. Rejuva, a novel device and AAV-mediated delivery platform, delivers gene therapy directly targeting the pancreas. This potentially embeds multiple different pharmacologies to address serious metabolic diseases, including type 2 diabetes and obesity.

According to a news release, Fractyl presented data at the World Congress of Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles last week.

“Today’s Rejuva program preclinical results represent the first demonstration of sustained, dose-dependent efficacy of a gene therapy targeting the GLP-1 receptor pathway in the pancreas in a rodent model of type 2 diabetes and obesity,” said Dr. Harith Rajagopalan, co-founder and CEO of Fractyl Health. “Results show that a single dose islet-targeted GLP-1 receptor agonist gene therapy candidate can induce sustained production of the transgene in pancreatic islets, delay disease progression, improve insulin production, and reduce blood glucose levels for up to ten weeks of follow-up.”

More on the Rejuva system

Rejuva encompasses both AAV-delivered transgenes and device-based delivery systems. Data in the current study include dose-dependent in vivo pharmacology and efficacy data. It covers an AAV-mediated gene therapy of a GLP-1 receptor agonist candidate in a db/db rodent model of type 2 diabetes.

Fracytl plans to present further large animal procedure data for Rejuva in 2023. The company called it “encouraging” feasibility data.

Rajagopalan said the local delivery devices and methods could “potentially enable pancreatic gene therapy to become a reality for the first time.”

“In many gene therapy programs, local delivery is demonstrating the potential to reduce viral load and associated risk of systemic administration, and we believe the same could be true for the pancreas,” said Rajagopalan. “Taken together, our Revita and Rejuva programs have the potential to address root cause pathology in two organs that are diseased in T2D: the gut and the pancreas.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Fractyl Health

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS